Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

1.1K
This protocol describes a blockade assay for PD-1/PD-L1 inhibitors using surface plasmon resonance technology. It employs a dual-step immobilization strategy and a tailored buffer system to accurately measure response units, facilitating the assessment of blockade rates for compounds or biologics. Additionally, it supports the high-throughput identification of PD-1/PD-L1...
1.1K
Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

1.7K
Checkpoint inhibitors are important targets in developing therapies for the battle against cancer. This report introduces a novel PDL1 peptide-based cancer vaccine, PDL1-Vaxx, which induces neutralizing polyclonal antibody production that blocks PD-1/PDL1 complex formation. This work also details the development and testing of a fluorescent bead-based assay for analyzing this...
1.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

1.1K
This study illustrates the methodological potential of combining Yttrium-90 Trans-Arterial Radioembolization (Y-90 TARE) with an anti-PD-1 monoclonal antibody as an effective neoadjuvant strategy leading to hepatectomy in hepatocellular carcinoma (HCC) patients with a high initial recurrence risk. It emphasizes the safety, feasibility, and step-by-step procedural guidance of this...
1.1K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

11.0K
To expand the ability of laboratories worldwide to assess the eligibility of patients with lung cancer for treatment with pembrolizumab, in a reliable and reproducible manner, we developed an assay that uses the 22C3 antibody concentrate on a widely available immunohistochemical autostainer, for both biopsy and cytology...
11.0K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

18.1K
Here we describe a minimally invasive syngeneic orthotopic transplantation model of mouse lung adenocarcinoma cells as a time- and cost-reducing model to study non-small cell lung...
18.1K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

6.1K
We developed a simple flow cytometry assay for evaluating the binding of PD-1–blocking antibodies to T cells, requiring only a drop of peripheral blood from cancer...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

YB-3 substitutes YB-1 in global mRNA binding.

RNA biology·2020
Same author

Hydroxycobalamin catalyzes the oxidation of diethyldithiocarbamate and increases its cytotoxicity independently of copper ions.

Redox biology·2018
Same author

Author Correction: Long-range non-diffusive spin transfer in a Hall insulator.

Scientific reports·2018
Same author

Long-range non-diffusive spin transfer in a Hall insulator.

Scientific reports·2018
Same author

Methods for Screening Live Cells.

Biochemistry. Biokhimiia·2018
Same author

Laser-synthesized oxide-passivated bright Si quantum dots for bioimaging.

Scientific reports·2016

Related Experiment Video

Updated: Jan 19, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K

T-Cell Engagers Based Bioassay for Evaluation of PD-1/PD-L1 Inhibitors Activity.

A N Doronin1,2, A A Gordeev1,2, A E Kozlov1

  • 1BIOCAD, Lyubuchany, Moscow Region, 142380, Russia.

Biochemistry. Biokhimiia
|September 12, 2019
PubMed
Summary

This study developed a novel cell-based bioassay for evaluating the activity of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antibodies. The assay, utilizing bispecific T-cell engagers, is crucial for advancing cancer immunotherapy development.

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.1K

Related Experiment Videos

Last Updated: Jan 19, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.1K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapies represent a significant advancement in cancer treatment.
  • Numerous anti-PD-1 and anti-PD-L1 antibodies are in development, necessitating robust methods for activity characterization.
  • Accurate bioassays are essential for determining the biological activity of these immunotherapeutic antibodies.

Purpose of the Study:

  • To develop and characterize a novel cell-based bioassay for analyzing the activity of anti-PD-1 and anti-PD-L1 antibodies.
  • To compare different effector cell activation strategies for their suitability in the bioassay.
  • To demonstrate the bioassay's applicability in the development and characterization of therapeutic agents.

Main Methods:

  • Development of a two-cell-line reporter system.
  • Evaluation of effector cell activation using superantigens, soluble anti-CD3, transmembrane anti-CD3, chimeric antigenic receptors (CARs), and bispecific T-cell engager antibodies.
  • Characterization of the developed bioassay's performance.

Main Results:

  • Bispecific T-cell engager antibodies demonstrated advantages for effector cell activation within the reporter system.
  • The developed cell-based bioassay was successfully characterized.
  • The bioassay proved applicable for analyzing the activity of anti-PD-1 and anti-PD-L1 antibodies.

Conclusions:

  • A novel and effective cell-based bioassay for PD-1/PD-L1 antibody activity analysis has been established.
  • The bioassay, particularly with bispecific T-cell engagers, offers a valuable tool for immunotherapy research.
  • This assay can support the development and characterization of new cancer therapeutic agents.